BIIB : Summary for Biogen Inc. - Yahoo Finance

U.S. Markets close in 44 mins.

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
280.21-6.67 (-2.33%)
As of 3:16PM EDT. Market open.
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close286.89
Bid280.09 x 300
Ask280.21 x 200
Day's Range279.57 - 286.62
52 Week Range223.02 - 333.65
Avg. Volume1,647,224
Market Cap60.51B
PE Ratio (TTM)16.55
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals21 minutes ago

    ​Hyde Park boy with rare disease wins appeal, will receive Biogen drug

    Doug Hansen of Hyde Park said he has won his appeal of a coverage decision by Neighborhood Health Plan, overturning the health insurance company's refusal to pay for an expensive new drug by Biogen to treat his 11-year-old son, Tyler. Tyler Hansen has spinal muscular atrophy, a very rare disease that that reduces ability to control voluntary muscle movement. The first-ever drug to treat the disease, called Spinraza and marketed by Cambridge-based Biogen (BIIB), was just approved by the Food and Drug Administration in December, and Tyler was prescribed the drug in early February.

  • Zacks5 hours ago

    Stock Market News for April 26, 2017

    Benchmarks finished in the green on Tuesday, following the release of strong earnings reports and as expectation for possible tax reform grew

  • Thomson Reuters StreetEvents6 hours ago

    Edited Transcript of BIIB earnings conference call or presentation 25-Apr-17 12:30pm GMT

    Q1 2017 Biogen Inc Earnings Call